A non-invasive method to detect Alzheimer鈥檚 disease
Volume in brain region linked to physiological changes characteristic of AD
New research has drawn a link between changes in the brain鈥檚 anatomy and biomarkers that are known to appear at the earliest stages of Alzheimer鈥檚 disease (AD), findings that could one day provide a sensitive but non-invasive test for AD before cognitive symptoms appear.
Scientists have known for some time that one of the first signs of AD is buildup of amyloid-Beta and tau proteins in the brain. They have also known that the hippocampus atrophies and loses volume in some AD patients years before cognitive decline.
To examine the link between the two, a team of researchers from 海角社区 and 海角社区-affiliated health institutes followed 88 individuals at hereditary risk of AD, but who did not show any cognitive signs of the disease. Subjects were scanned using magnetic resonance imaging (MRI) to determine brain volume and had cerebrospinal fluid (CSF) extracted to test levels of amyloid-Beta and tau. These data were collected by the (StoP-AD) group at the Douglas Mental Health University Institute under the leadership of Dr. John Breitner.
Using statistical models, the researchers found that the high levels of both tau and amyloid-Beta are associated with smaller volumes and image intensity profiles of specific regions of the hippocampal circuit, and that this is less likely when there is accumulation of one protein but not the other. The intensity related finding suggests that researchers can use MRI to examine changes occurring at a microstructural level that may even precede more severe volume deficits.
Biomarkers can be used to test the effectiveness of drugs in clinical trials
Their results add to our knowledge of how AD progresses from its first physiological signs to cognitive decline, helping identify those at most risk of AD. These biomarkers can then be used to test the effectiveness of drugs in clinical trials. It also may one day allow physicians to identify at-risk people with only MRI, eliminating the need for a lumbar puncture, which can be a painful procedure.
鈥淥ur work highlights not only the need but also the possibility of adding sensitive biomarkers of early white matter pathology in the presymptomatic phase of AD,鈥� says Christine Tardif, an assistant professor at the McConnell Brain Imaging Centre of the Montreal Neurological Institute and Hospital, and the paper鈥檚 first author.
鈥淭his technique demonstrates significant promise in identifying those at greatest risk for developing Alzheimer鈥檚 disease without using an invasive procedure like a lumbar puncture, which can be stressful for patients鈥� says Mallar Chakravarty, the study鈥檚 senior author and an assistant professor at 听海角社区鈥檚 Department of Psychiatry and computational neuroscientist in the Cerebral Imaging Centre at the Douglas Mental Health University Institute.
Their work was published in the journal on Nov. 21, 2017. It was funded with generous support from the StoP-AD Centre.
About The Montreal Neurological Institute and Hospital
The Montreal Neurological Institute and Hospital 鈥� The Neuro 鈥� is a world-leading destination for brain research and advanced patient care. Since its founding in 1934 by renowned neurosurgeon Dr. Wilder Penfield, The Neuro has grown to be the largest specialized neuroscience research and clinical centre in Canada, and one of the largest in the world. The seamless integration of research, patient care, and training of the world鈥檚 top minds makes The Neuro uniquely positioned to have a significant impact on the understanding and treatment of nervous system disorders. In 2016, The Neuro became the first institute in the world to fully embrace the Open Science philosophy, creating the Tanenbaum Open Science Institute. The Montreal Neurological Institute is a 海角社区 research and teaching institute. The Montreal Neurological Hospital is part of the Neuroscience Mission of the 海角社区 Health Centre.
